San Diego, California, June 15, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (GHSI) (Nasdaq: GHSI) announced today that its Board of Directors has appointed Dr. David Evans, Ph.D. as the Company's Interim President and Interim Chief Executive Officer effective immediately. Dr. Evans has served as the Company’s Chief Science Officer and was the founder of the Company’s subsidiary, VectorVision. Dr. Evans joined the Guardion Board of Directors effective with the Company’s acquisition of VectorVision on September 29, 2017.

David Evans succeeds Michael Favish, who is the founder of Guardion and who is stepping down as an officer and employee of Guardion and is also leaving the Board of Directors of Guardion.

Dr. Evans commented, “The Board of Directors would like to thank Mr. Favish for his leadership and service to Guardion for these past years.”

Dr. Evans continued, “Guardion has successfully raised much needed capital and strengthened the Company’s balance sheet through the Company’s initial public offering and follow-on public offerings in 2019, and is now focusing on refining and executing its business plan in order to effectively deploy its capital, improve the financial and operational performance of its business units, and enhance long-term stockholder value.”

The Board is conducting an extensive search to identify the Company’s next Chief Executive Officer and will provide additional information to shareholders as it becomes available.

About Guardion Health Sciences, Inc.

Guardion is a specialty health sciences company (i) that develops medical foods and medical devices in the ocular health marketplace and (ii) that is developing nutraceuticals that the Company believes will provide medicinal and health benefits to consumers. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.

About VectorVision^®

VectorVision^® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision’s^® patented technology is considered the standard of care for clinical trials. VectorVision^® is a wholly owned subsidiary of Guardion.